has function has role immunizes against disease immunizes recipient lymphoma Homo sapiens therapeutic vaccine function vaccine in clinical trial role lymphoma vaccine Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells Cancer Vaccine 5411 Gene name: MS4A1 Eliyas Asfaw Oliver He Jie Zheng https://www.targetedonc.com/view/cd20-cd3-bispecific-antibodies-can-revolutionize-b-cell-lymphoma-therapy Ibrahim Seleznev 931 Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors. VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5411 cancer vaccine https://github.com/vaccineontology/VO/issues/225 therapeutic cancer vaccine